Login
$XTNT
$0.21 -$0.06 (23.33%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Sean E. Browne Also a director
President and Chief Executive Officer and Director
60 Not stated Not stated $1,351,676
Scott C. Neils
Chief Financial Officer and Assistant Secretary
42 Not stated Not stated $939,369
Mark A. Schallenberger
Chief Operating Officer
40 Since 2025
1 year
2010 $1,110,531

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
5 of 5
stated in the proxy; 1 not stated
Average tenure
4.0 years
from year joined
CEO also chairs the board
No
Stavros G. Vizirgianakis
Director Age On board Independent Committees Other public boards 2025 pay Source
Stavros G. Vizirgianakis
55 2022
4 years
Independent
Nominating and Corporate Governance Committee · Chair
Apyx Medical Corporation (NASDAQ: APYX) $477,052
Sean E. Browne
60 2019
7 years
Not stated None stated None stated Paid as CEO
John K. Bakewell
65 2018
8 years
Independent
Audit Committee · Chair
Treace Medical Concepts, Inc. (NASDAQ: TMCI) $185,348
Jonn R. Beeson
57 2023
3 years
Independent
Audit Committee Compensation Committee · Chair
None stated $185,713
Abhinav Jain
35 2025
1 year
Independent
Compensation Committee
Aytu Biopharma, Inc. (NASDAQ: AYTU) $131,233
Tyler P. Lipschultz
59 2025
1 year
Independent None stated None stated $133,838

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Jun 23, 2026
Nantahala Capital Management, LLC
beneficial owner of more than 5% of our common stock as of April 10, 2025
Amount not stated
2025

Funds affiliated with Nantahala purchased shares from the OrbiMed Sellers under a stock purchase agreement; the company entered into a registration rights agreement with the Purchasers.

With OrbiMed Sellers Open in proxy
Carol Ann Vizirgianakis
the mother of Stavros G. Vizirgianakis, a director of the Company and Chairman of the Board
Amount not stated
2025

Purchased shares of common stock from the OrbiMed Sellers under the April 10, 2025 stock purchase agreement (73,114,592 shares in aggregate at $0.42 per share).

With OrbiMed Sellers Open in proxy
OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP
former majority stockholders of the Company, affiliates of OrbiMed Advisors LLC
Amount not stated
2025

Investor Rights Agreement granting governance and other rights (director nomination, special approval, rights of first refusal), terminated by the company on April 15, 2025.

With Royalty Opportunities and ROS Open in proxy
Stavros G. Vizirgianakis
a director and Chairman of the Board
Amount not stated

Agreement under which the company granted director nomination rights as lead investor of the 2022 private placement; the nomination rights terminated October 7, 2024, and a corporate opportunities provision remains in place.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support